nodes	percent_of_prediction	percent_of_DWPC	metapath
Brinzolamide—Pruritus—Mechlorethamine—lymphatic system cancer	0.00457	0.00457	CcSEcCtD
Brinzolamide—Cough—Fludarabine—lymphatic system cancer	0.00448	0.00448	CcSEcCtD
Brinzolamide—Hypotension—Teniposide—lymphatic system cancer	0.00445	0.00445	CcSEcCtD
Brinzolamide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00442	0.00442	CcSEcCtD
Brinzolamide—Myalgia—Fludarabine—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Brinzolamide—Arthralgia—Fludarabine—lymphatic system cancer	0.00437	0.00437	CcSEcCtD
Brinzolamide—Discomfort—Fludarabine—lymphatic system cancer	0.00432	0.00432	CcSEcCtD
Brinzolamide—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.0043	0.0043	CcSEcCtD
Brinzolamide—Dyspnoea—Teniposide—lymphatic system cancer	0.00425	0.00425	CcSEcCtD
Brinzolamide—Depression—Carmustine—lymphatic system cancer	0.00419	0.00419	CcSEcCtD
Brinzolamide—Infection—Fludarabine—lymphatic system cancer	0.00416	0.00416	CcSEcCtD
Brinzolamide—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Brinzolamide—Decreased appetite—Teniposide—lymphatic system cancer	0.00414	0.00414	CcSEcCtD
Brinzolamide—Vomiting—Mechlorethamine—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Brinzolamide—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Brinzolamide—Rash—Mechlorethamine—lymphatic system cancer	0.00407	0.00407	CcSEcCtD
Brinzolamide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00407	0.00407	CcSEcCtD
Brinzolamide—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00404	0.00404	CcSEcCtD
Brinzolamide—Depression—Vincristine—lymphatic system cancer	0.004	0.004	CcSEcCtD
Brinzolamide—Feeling abnormal—Teniposide—lymphatic system cancer	0.00393	0.00393	CcSEcCtD
Brinzolamide—Nausea—Mechlorethamine—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Brinzolamide—Alopecia—Bleomycin—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Brinzolamide—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Brinzolamide—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.0038	0.0038	CcSEcCtD
Brinzolamide—Urticaria—Teniposide—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Brinzolamide—Erythema—Bleomycin—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Brinzolamide—Paraesthesia—Fludarabine—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Brinzolamide—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00375	0.00375	CcSEcCtD
Brinzolamide—Dyspnoea—Fludarabine—lymphatic system cancer	0.00373	0.00373	CcSEcCtD
Brinzolamide—Oedema peripheral—Carmustine—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Brinzolamide—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00371	0.00371	CcSEcCtD
Brinzolamide—Dyspepsia—Fludarabine—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Brinzolamide—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Brinzolamide—Decreased appetite—Fludarabine—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Brinzolamide—Visual impairment—Carmustine—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Brinzolamide—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Brinzolamide—Fatigue—Fludarabine—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Brinzolamide—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Brinzolamide—Pain—Fludarabine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Brinzolamide—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Brinzolamide—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Brinzolamide—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Brinzolamide—Urethral disorder—Vincristine—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Brinzolamide—Eye disorder—Carmustine—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Brinzolamide—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Brinzolamide—Hypersensitivity—Teniposide—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Brinzolamide—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00349	0.00349	CcSEcCtD
Brinzolamide—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Brinzolamide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Brinzolamide—Asthenia—Teniposide—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Brinzolamide—Malaise—Bleomycin—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Brinzolamide—Pruritus—Teniposide—lymphatic system cancer	0.00337	0.00337	CcSEcCtD
Brinzolamide—Arrhythmia—Carmustine—lymphatic system cancer	0.00337	0.00337	CcSEcCtD
Brinzolamide—Cardiac disorder—Vincristine—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Brinzolamide—Alopecia—Carmustine—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Brinzolamide—Mental disorder—Carmustine—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Brinzolamide—Erythema—Carmustine—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Brinzolamide—Malnutrition—Carmustine—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Brinzolamide—Cough—Bleomycin—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Brinzolamide—Angiopathy—Vincristine—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Brinzolamide—Diarrhoea—Teniposide—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Brinzolamide—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Brinzolamide—Myalgia—Bleomycin—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Brinzolamide—Chest pain—Bleomycin—lymphatic system cancer	0.0032	0.0032	CcSEcCtD
Brinzolamide—Alopecia—Vincristine—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Brinzolamide—Back pain—Carmustine—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Brinzolamide—Discomfort—Bleomycin—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Brinzolamide—Mental disorder—Vincristine—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Brinzolamide—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Brinzolamide—Alopecia—Mitoxantrone—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Brinzolamide—Vision blurred—Carmustine—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Brinzolamide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Brinzolamide—Tremor—Carmustine—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Brinzolamide—Erythema—Mitoxantrone—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Brinzolamide—Infection—Bleomycin—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Brinzolamide—Back pain—Vincristine—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Brinzolamide—Vomiting—Teniposide—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Brinzolamide—Agitation—Carmustine—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Brinzolamide—Asthenia—Fludarabine—lymphatic system cancer	0.003	0.003	CcSEcCtD
Brinzolamide—Rash—Teniposide—lymphatic system cancer	0.003	0.003	CcSEcCtD
Brinzolamide—Dermatitis—Teniposide—lymphatic system cancer	0.003	0.003	CcSEcCtD
Brinzolamide—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Brinzolamide—Headache—Teniposide—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Brinzolamide—Pruritus—Fludarabine—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Brinzolamide—Back pain—Mitoxantrone—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Brinzolamide—Agitation—Vincristine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Brinzolamide—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Brinzolamide—Hypotension—Bleomycin—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Brinzolamide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Brinzolamide—Hypertension—Carmustine—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Brinzolamide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Brinzolamide—Nausea—Teniposide—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Brinzolamide—Vertigo—Vincristine—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Brinzolamide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Brinzolamide—Chest pain—Carmustine—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Brinzolamide—Myalgia—Carmustine—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Brinzolamide—Paraesthesia—Bleomycin—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Brinzolamide—Malaise—Mitoxantrone—lymphatic system cancer	0.00275	0.00275	CcSEcCtD
Brinzolamide—Dyspnoea—Bleomycin—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Brinzolamide—Hypertension—Vincristine—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Brinzolamide—Decreased appetite—Bleomycin—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Brinzolamide—Myalgia—Vincristine—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Brinzolamide—Visual disturbance—Methotrexate—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Brinzolamide—Cough—Mitoxantrone—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Brinzolamide—Infection—Carmustine—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Brinzolamide—Vomiting—Fludarabine—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Brinzolamide—Rash—Fludarabine—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Brinzolamide—Dermatitis—Fludarabine—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Brinzolamide—Hypertension—Mitoxantrone—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Brinzolamide—Pain—Bleomycin—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Brinzolamide—Headache—Fludarabine—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Brinzolamide—Tachycardia—Carmustine—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Brinzolamide—Myalgia—Mitoxantrone—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Brinzolamide—Chest pain—Mitoxantrone—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Brinzolamide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Brinzolamide—Discomfort—Mitoxantrone—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Brinzolamide—Infection—Vincristine—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Brinzolamide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Brinzolamide—Nervous system disorder—Vincristine—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Brinzolamide—Hypotension—Carmustine—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Brinzolamide—Nausea—Fludarabine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Brinzolamide—Infection—Mitoxantrone—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Brinzolamide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Brinzolamide—Urticaria—Bleomycin—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Brinzolamide—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Brinzolamide—Insomnia—Carmustine—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Brinzolamide—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00242	0.00242	CcSEcCtD
Brinzolamide—Irritability—Methotrexate—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Brinzolamide—Paraesthesia—Carmustine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Brinzolamide—Hypotension—Vincristine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Brinzolamide—Dyspnoea—Carmustine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Brinzolamide—Somnolence—Carmustine—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Brinzolamide—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Brinzolamide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Brinzolamide—Decreased appetite—Carmustine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Brinzolamide—Hypotension—Mitoxantrone—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Brinzolamide—Insomnia—Vincristine—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Brinzolamide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Brinzolamide—Paraesthesia—Vincristine—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Brinzolamide—Pain—Carmustine—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Brinzolamide—Breast disorder—Methotrexate—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Brinzolamide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Brinzolamide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Brinzolamide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Brinzolamide—Decreased appetite—Vincristine—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Brinzolamide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Brinzolamide—Somnolence—Mitoxantrone—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Brinzolamide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Brinzolamide—Feeling abnormal—Carmustine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Brinzolamide—Fatigue—Vincristine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Brinzolamide—Asthenia—Bleomycin—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Brinzolamide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Brinzolamide—Pain—Vincristine—lymphatic system cancer	0.00219	0.00219	CcSEcCtD
Brinzolamide—Asthma—Methotrexate—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Brinzolamide—Pruritus—Bleomycin—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Brinzolamide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Brinzolamide—Fatigue—Mitoxantrone—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Brinzolamide—Pain—Mitoxantrone—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Brinzolamide—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Brinzolamide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Brinzolamide—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Brinzolamide—Urticaria—Mitoxantrone—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Brinzolamide—Hypersensitivity—Carmustine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Brinzolamide—Vomiting—Bleomycin—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Brinzolamide—Infestation NOS—Methotrexate—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Brinzolamide—Infestation—Methotrexate—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Brinzolamide—Depression—Methotrexate—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Brinzolamide—Rash—Bleomycin—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Brinzolamide—Dermatitis—Bleomycin—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Brinzolamide—Asthenia—Carmustine—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Brinzolamide—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Brinzolamide—Hypersensitivity—Vincristine—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Brinzolamide—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Brinzolamide—Epistaxis—Methotrexate—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Brinzolamide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Brinzolamide—Asthenia—Vincristine—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Brinzolamide—Diarrhoea—Carmustine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Brinzolamide—Nausea—Bleomycin—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Brinzolamide—Asthenia—Mitoxantrone—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Brinzolamide—Dizziness—Carmustine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Brinzolamide—Diarrhoea—Vincristine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Brinzolamide—Pharyngitis—Methotrexate—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Brinzolamide—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Brinzolamide—Urethral disorder—Methotrexate—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Brinzolamide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Brinzolamide—Vomiting—Carmustine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Brinzolamide—Dizziness—Vincristine—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Brinzolamide—Rash—Carmustine—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Brinzolamide—Dermatitis—Carmustine—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Brinzolamide—Visual impairment—Methotrexate—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Brinzolamide—Headache—Carmustine—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Brinzolamide—Eye disorder—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Brinzolamide—Tinnitus—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Brinzolamide—Vomiting—Vincristine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Brinzolamide—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Brinzolamide—Rash—Vincristine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Brinzolamide—Dermatitis—Vincristine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Brinzolamide—Headache—Vincristine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Brinzolamide—Nausea—Carmustine—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Brinzolamide—Angiopathy—Methotrexate—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Brinzolamide—Vomiting—Mitoxantrone—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Brinzolamide—Immune system disorder—Methotrexate—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Brinzolamide—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Brinzolamide—Rash—Mitoxantrone—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Brinzolamide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Brinzolamide—Headache—Mitoxantrone—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Brinzolamide—Alopecia—Methotrexate—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Brinzolamide—Mental disorder—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Brinzolamide—Erythema—Methotrexate—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Brinzolamide—Malnutrition—Methotrexate—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Brinzolamide—Nausea—Vincristine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Brinzolamide—Dysgeusia—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Brinzolamide—Nausea—Mitoxantrone—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Brinzolamide—Back pain—Methotrexate—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Brinzolamide—Vision blurred—Methotrexate—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Brinzolamide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Brinzolamide—Malaise—Methotrexate—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Brinzolamide—Vertigo—Methotrexate—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Brinzolamide—Cough—Methotrexate—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Brinzolamide—Arthralgia—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Brinzolamide—Myalgia—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Brinzolamide—Chest pain—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Brinzolamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Brinzolamide—Discomfort—Methotrexate—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Brinzolamide—Infection—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Brinzolamide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Brinzolamide—Skin disorder—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Brinzolamide—Hypotension—Methotrexate—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Brinzolamide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Brinzolamide—Insomnia—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Brinzolamide—Paraesthesia—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Brinzolamide—Dyspnoea—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Brinzolamide—Somnolence—Methotrexate—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Brinzolamide—Dyspepsia—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Brinzolamide—Decreased appetite—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Brinzolamide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Brinzolamide—Fatigue—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Brinzolamide—Pain—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Brinzolamide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Brinzolamide—Urticaria—Methotrexate—lymphatic system cancer	0.000986	0.000986	CcSEcCtD
Brinzolamide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000915	0.000915	CcSEcCtD
Brinzolamide—Asthenia—Methotrexate—lymphatic system cancer	0.000891	0.000891	CcSEcCtD
Brinzolamide—Pruritus—Methotrexate—lymphatic system cancer	0.000878	0.000878	CcSEcCtD
Brinzolamide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000849	0.000849	CcSEcCtD
Brinzolamide—Dizziness—Methotrexate—lymphatic system cancer	0.000821	0.000821	CcSEcCtD
Brinzolamide—Vomiting—Methotrexate—lymphatic system cancer	0.000789	0.000789	CcSEcCtD
Brinzolamide—Rash—Methotrexate—lymphatic system cancer	0.000783	0.000783	CcSEcCtD
Brinzolamide—Dermatitis—Methotrexate—lymphatic system cancer	0.000782	0.000782	CcSEcCtD
Brinzolamide—Headache—Methotrexate—lymphatic system cancer	0.000778	0.000778	CcSEcCtD
Brinzolamide—Nausea—Methotrexate—lymphatic system cancer	0.000737	0.000737	CcSEcCtD
